ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0703

Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect

Francis Berenbaum1, Coralie Meurot2, Laure Sudre3, Keren Bismuth2, Revital Rattenbach2, Patrice Denefle2, Celine Martin2 and Claire Jacques3, 1AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, 2Campus Institut Pasteur Lille, 4P Pharma, Lille, France, 3Inserm, UMR_S938, Hospital Saint-Antoine, Paris, France

Meeting: ACR Convergence 2020

Keywords: Chondrogenesis, Mouse Models, Other, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Osteoarthritis & Joint Biology – Basic Science Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoarthritis (OA) is an age-related joint disease affecting millions of individuals worldwide and associated with an extremely high burden largely attributable to disability. To date, there are only symptomatic treatments and no disease-modifying OA drugs (DMOADs) acting on both symptoms and structure are yet approved. Although OA is a disorder of the whole joint, progressive cartilage degeneration is considered as its hallmark. Indeed, differentiation and function of chondrocytes are impaired in OA, resulting in the breakdown of the cartilage matrix. Liraglutide is a Glucagon-Like-Peptide 1 Receptor (GLP-1R) agonist widely prescribed for the treatment of type 2 diabetes. We have previously shown that intra-articular (IA) liraglutide exerts anti-inflammatory and anti-degradative effects1. In this study, liraglutide was assessed for its pro-chondrogenic properties.

Methods: IA injection of liraglutide or vehicle was performed 2 days after injection of monoiodoacetate (MIA) or saline in mice. RTqPCR analyses of knee joint was performed 10 days following saline or MIA injection. The capacity of liraglutide (10-500nM) to induce chondrogenesis was evaluated using human mesenchymal stem cells (hMSCs) and mouse embryonic fibroblasts (MEFs) high-density micromass in-well culture systems. Safranin O and/or alcian blue staining was used to assess differentiation into chondrocytes. Exendin 9-39, a GLP-1R antagonist, was used to confirm target specificity. A commercial differentiation medium and bone morphogenetic protein 2 (BMP-2) were used as positive controls for hMSC and MEFs models, respectively.

Results: Col2a1 gene expression was significantly increased in total knee joints from MIA-induced mice treated with 30µg of liraglutide compared to vehicle (At Day 11, Liraglutide= 1.96±1.34, vs vehicle= 0.64±0.46, p< 0.05, fold change related to saline treatment). Moreover, there was a significant induction of Sox9 gene expression in MIA mice treated with 30µg and 20µg of liraglutide (Fold 2.46±1.84; 2.08±1.36, respectively, p≤0.05) compared to vehicle (0.92±0.67). Using hMSC, after 21 days of treatment, liraglutide but not vehicle induced their differentiation into chondrogenic 3D spheroids (Liraglutide 10nM= 5 alcian-blue positive spheroids out of 6 counted wells, p< 0.05; Liraglutide 100nM= 4/6, p=0.06, vs vehicle= 0/6). 5/6 alcian-blue positive spheroids were also observed for the positive control. Both Liraglutide or BMP-2 induced MEFs to differentiate into chondrocytes as revealed by cytologic analysis using alcian blue and safranin O staining. Spectroscopic quantification (in arbitrary unit, AU) of the Safranin O stain in MEFs after 21 days of chondrogenic differentiation indicated a significant increase of absorbance for liraglutide 500nM (2.90±0.03 AU, p< 0.001) and BMP-2 (3.17±0.06, p< 0.001) vs vehicle (1.99±0.34). The use of exendin 9-39 confirmed that the effect of liraglutide on chondrogenesis was GLP-1R dependent in both in vitro models.

Conclusion: Liraglutide promotes chondrocyte differentiation, which could facilitate cartilage regeneration in OA, and thus represents a potential DMOAD treatment for knee OA.

  1. Berenbaum et al, Arthritis Rheumatol. 2019; 71 (s10).

Disclosure: F. Berenbaum, Pfizer, 1, Eli Lilly, 1; C. Meurot, None; L. Sudre, None; K. Bismuth, None; R. Rattenbach, None; P. Denefle, None; C. Martin, None; C. Jacques, None.

To cite this abstract in AMA style:

Berenbaum F, Meurot C, Sudre L, Bismuth K, Rattenbach R, Denefle P, Martin C, Jacques C. Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/liraglutide-as-a-potential-intra-articular-treatment-for-cartilage-regeneration-in-osteoarthritis-in-vitro-and-in-vivo-studies-supporting-a-pro-chondrogenic-effect/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/liraglutide-as-a-potential-intra-articular-treatment-for-cartilage-regeneration-in-osteoarthritis-in-vitro-and-in-vivo-studies-supporting-a-pro-chondrogenic-effect/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology